Zobraziť v EDS

Imeglimin as an effective therapeutic approach in management of type 2 diabetes mellitus: an umbrella review and systematic review, meta-regression and meta-analysis

Uložené v:
Podrobná bibliografia
Názov: Imeglimin as an effective therapeutic approach in management of type 2 diabetes mellitus: an umbrella review and systematic review, meta-regression and meta-analysis
Autori: Qian Song, Rui Mae, Emad Kutbi, Abdullah Nasser AlJurayyan, Ahmed Abu-Zaid, Parsa Jamilian, Maryam Falahatzadeh
Zdroj: Diabetology & Metabolic Syndrome, Vol 17, Iss 1, Pp 1-15 (2025)
Informácie o vydavateľovi: BMC, 2025.
Rok vydania: 2025
Zbierka: LCC:Nutritional diseases. Deficiency diseases
Predmety: Imeglimin, Diabetes mellitus, Glycemic, Umbrella, Meta-analysis, Nutritional diseases. Deficiency diseases, RC620-627
Popis: Abstract Background Imeglimin as a novel antidiabetic agent has emerged promising effects compared to previously established treatments. This updated systematic review and meta-analysis and umbrella review evaluated the efficacy and safety of Imeglimin in managing Type 2 Diabetes Mellitus (T2DM). Methods A systematic search of PubMed, Scopus, Web of Science, Embase, and Cochrane Central was conducted up to June 2025. Randomized controlled trials (RCTs) with at least 12 weeks of follow-up, involving adult T2DM patients, were included. Data were independently extracted by two reviewers, and any discrepancies were resolved by a third investigator. Outcomes were pooled using random-effects or fixed-effects models based on heterogeneity. The quality of the included trials was assessed using the Cochrane Risk of Bias 2.0 tool. Also, the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach was used to evaluate the certainty of evidence. Results Twelve RCTs evaluating the effect of imeglimin on metabolic factors were included. Imeglimin significantly reduced fasting plasma glucose (FPG) (SMD: -0.51; 95% CI: -0.72, -0.29, P 0.05). However, its unfavorable effect was shown in term of LDL (SMD: 0.32; 95% CI: 0.11, 0.53, P = 0.017; I 2 = 0.0%, P-heterogeneity = 0.68). Conclusion Imeglimin has demonstrated efficacy and a favorable safety profile in the management of T2DM, particularly regarding glycemic control and lipid profile. Further large-scale trials across diverse populations are warranted to confirm these outcomes.
Druh dokumentu: article
Popis súboru: electronic resource
Jazyk: English
ISSN: 1758-5996
Relation: https://doaj.org/toc/1758-5996
DOI: 10.1186/s13098-025-01922-2
Prístupová URL adresa: https://doaj.org/article/5404a8c851a044daa57bfaeb0b1e5dfa
Prístupové číslo: edsdoj.5404a8c851a044daa57bfaeb0b1e5dfa
Databáza: Directory of Open Access Journals
Popis
Abstrakt:Abstract Background Imeglimin as a novel antidiabetic agent has emerged promising effects compared to previously established treatments. This updated systematic review and meta-analysis and umbrella review evaluated the efficacy and safety of Imeglimin in managing Type 2 Diabetes Mellitus (T2DM). Methods A systematic search of PubMed, Scopus, Web of Science, Embase, and Cochrane Central was conducted up to June 2025. Randomized controlled trials (RCTs) with at least 12 weeks of follow-up, involving adult T2DM patients, were included. Data were independently extracted by two reviewers, and any discrepancies were resolved by a third investigator. Outcomes were pooled using random-effects or fixed-effects models based on heterogeneity. The quality of the included trials was assessed using the Cochrane Risk of Bias 2.0 tool. Also, the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach was used to evaluate the certainty of evidence. Results Twelve RCTs evaluating the effect of imeglimin on metabolic factors were included. Imeglimin significantly reduced fasting plasma glucose (FPG) (SMD: -0.51; 95% CI: -0.72, -0.29, P 0.05). However, its unfavorable effect was shown in term of LDL (SMD: 0.32; 95% CI: 0.11, 0.53, P = 0.017; I 2 = 0.0%, P-heterogeneity = 0.68). Conclusion Imeglimin has demonstrated efficacy and a favorable safety profile in the management of T2DM, particularly regarding glycemic control and lipid profile. Further large-scale trials across diverse populations are warranted to confirm these outcomes.
ISSN:17585996
DOI:10.1186/s13098-025-01922-2